1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIBIB Exploratory/Development (R21) Grant is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Exploratory/Developmental Grant Program - R21 | National Institute of Biomedical Imaging and Bioengineering Exploratory/Developmental Grant Program - R21 Division of Applied Science & Technology (Biomedical Imaging) Program Area: Photoacoustic and Optoacoustic Technologies The National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites investigator-initiated Exploratory/Developmental Grant (R21) applications relevant to its research mission.
NIBIB seeks to improve health by promoting fundamental discoveries, design and development, and translation and assessment of technological capabilities in biomedical imaging and bioengineering, enabled by relevant areas of information science, physics, chemistry, mathematics, materials science, and computer sciences.
All investigators should consult with the NIBIB staff contacts to determine if an R21 application is appropriate for NIBIB. All NIBIB R21 grant applications must be relevant or appropriate to the NIBIB program areas . Applications that are outside the mission and program areas of the NIBIB will be returned without review.
NIBIB supports hypothesis-, design-, technology-, or problem-driven research relating to its mission. Program areas of interest to the NIBIB include all aspects of biomedical imaging and bioengineering relevant to improving health. For a detailed description of the NIBIB scientific program areas, please visit the Programs page.
The NIBIB no longer participates in PAR-18-433, “NIH Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)” or in PA-16-040 “Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)s. NIBIB will continue to accept R21 applications under separate NIBIB/NIH Program Announcements such as: 1.
The NIBIB Trailblazer Award for New and Early Stage Investigators ( PA-25-169 ), which is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB (see Programs ) that integrate engineering and the physical sciences with the life and behavioral sciences.
This Notice of Funding Opportunity (NOFO), invites applications from researchers who are at the early stage of their independent careers or those who have not had substantial prior NIH funding (see NIH New and Early Stage Investigator definition). A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.
Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data. 2. The NIH Exploratory/Developmental Research Grant Program R21 Award (Parent R21 Clincal Trial Required, PA-25-306 ) and NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed, PA-25-304 ) supports exploratory/developmental research programs of interest to NIBIB (see Programs ).
These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. An R21 grant application need not have extensive background material or preliminary information.
Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R21 applications; however, they may be included if available. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project.
A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. The following notices announce the participation of NIBIB in the NIH Exploratory/Developmental Research Grant Program: PA-25-306 and PA-25-304 . 3.
R21 applications submitted in response to specific, topical NOFOs that the NIBIB is participating on that are not listed above. We highly encourage applicants to contact an NIBIB Program Officer to determine if your application fits the mission of the NIBIB and its Programs as well as our new funding strategies for R21s.
Projects from Investigators that are supported by preliminary data should be submitted to the Parent R01 NOFO, described in PA-25-305 or PA-25-301 . For more information about the NIBIB Exploratory/Developmental Research Grant Program R21, see our Frequently Asked Questions . For more information about the NIBIB R21 Trailblazer, see our Frequently Asked Questions .
We encourage your inquiries concerning NIBIB R21 grants and welcome the opportunity to answer questions from potential applicants.
According to the current listing, eligibility includes: Open to institutions and organizations proposing innovative research in biomedical imaging and bioengineering. Confirm the full requirements in the official notice before applying.
NIBIB Exploratory/Development (R21) Grant is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Small Business Innovation Research (SBIR)/ Small Business Technology Transfer... is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB Small Business Program supports the translation of cutting-edge technologies into commercial products to address critical healthcare challenges. These programs encourage research and development with a strong potential for technology commercialization.
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) that funds the translational development of innovative diagnostic and therapeutic medical devices.
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read article